Recently, the National Institutes of Health (NIH) announced that it is funding four final phase clinical trials of artificial pancreas devices. If the trial progresses well, these artificial pancreas are expected to be approved by the FDA.
$41 million in funding
The artificial pancreas is a special medical device that automatically monitors blood sugar levels in diabetic patients and provides insulin or other medications based on data. Compared with conventional diabetes treatments, artificial pancreas does not require frequent needle acupuncture to analyze blood sugar levels, nor does it require regular insulin injections. Instead, it integrates everything into one instrument to make patients' lives more Convenient.
To meet the patient's medical needs, Medtronic's first artificial pancreas was approved in October last year. This is a good start, but as a pioneer, patients who use this product still need to manually adjust the insulin intake after eating. In the eyes of NIH scientists, the ideal artificial pancreas should be fully automated for monitoring and administration. Even during mealtimes, you can cope with soaring blood sugar.
Therefore, NIH's National Institute of Diabetes, Digestive Diseases and Nephrology (NIDDK) will fund four different projects, hoping to improve the fully automatic artificial pancreas.
These devices differ in their method of use, but are intended to limit the amount of time that a diabetic patient or his caregiver must control changes in blood glucose levels. Funding for these programs comes from a special grant for type 1 diabetes treatment in the US Congress. Currently, the sum of these funds is as high as $41 million.
Four projects
The first project will test a fully automated insulin delivery system, inControl. It will use a smartphone to monitor 240 people with type 1 diabetes in the United States for 6 months. The project is recruiting patients; the second project will be launched earlier this year to monitor the use of artificial pancreas in 130 young diabetic patients. The third project will recruit 100 young diabetics to understand the feasibility of the “next generation of artificial pancreasâ€. This type of artificial pancreas has a special procedure to better control blood sugar during meals. It will be launched in the second half of this year.
The last project is even larger and is expected to begin in mid-2018, led by Dr. Steven Russell of Boston General Hospital in Boston and Ed Damiano of Boston University. The researchers plan to recruit 312 adults over the age of 18 for a six-month test. They will analyze the safety and efficacy of a "double hormone bionic pancreas". This bionic pancreas provides both insulin and glucagon. The researchers hope that the blood sugar levels of patients will remain stable under the action of these two functionally opposite hormones.
iLet, a device tested by Boston University Ed Damiano
The United States Food and Drug Administration (FDA) has published the Dietary Supplement Health and Education Act (DSHEA), which provides for dietary supplements. A product (other than tobacco) intended to supplement the diet may contain one or more of the following dietary ingredients: A vitamin, a mineral, an herb (herbal) or other plant, an amino acid, a food component used to increase the total daily intake to supplement the diet, or a concentrate, metabolite, component, extract or combination of the above ingredients, etc. It also includes approved new drugs, vitamins or biologics that have been marketed as dietary supplements or food products before they are approved, issued or licensed. The DSHEA defines dietary supplements as their composition and labeling requirements: the product form may be pill, capsule, tablet or liquid; The product shall not be used as a substitute for ordinary foods or as an exclusive dietary item. The product shall be labeled as a "dietary supplement".
Dietary Supplements,Arachidonic Acid Powder,Kava Root Powder,Kava Root Extract Powder
Xi'an Double H Health Technology Co., Ltd , https://www.dhextract.com